[Comparative efficacy of the long-term use of long-acting nitroglycerin (sustak) and molsidomine after myocardial infarct complicated by heart failure].
Clinical and hemodynamic efficiency of long-term treatment with sustak and molsidomin was assessed in 56 patients following myocardial infarction complicated by circulatory insufficiency within 9 months after discharge from hospital. In spite of the same mechanism of action, long-term treatment with these drugs produces different clinical and hemodynamic effects. The efficiency of prolonged and continuous sustak treatment is shown to decline after 3 months, as reflected in weaker antianginal and hemodynamic effects of the drug. Molsidomin, on the contrary, retains its positive clinical and hemodynamic effects throughout 9 months of use. The long-term use of the peripheral vasodilator molsidomin effectively prevents heart failure in myocardial infarction survivors.